Inovio Pharmaceuticals (Inovio Pharmaceuticals) EBIT per Share : $-6.06 (TTM As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals EBIT per Share?

Inovio Pharmaceuticals's EBIT per Share for the three months ended in Dec. 2023 was $-1.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.06.

During the past 3 years, the average EBIT per Share Growth Rate was 14.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 8.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was -4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Inovio Pharmaceuticals's EBIT per Share or its related term are showing as below:

INO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.2 Med: 7.55 Max: 33.3
Current: 14.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Inovio Pharmaceuticals was 33.30% per year. The lowest was -31.20% per year. And the median was 7.55% per year.

INO's 3-Year EBIT Growth Rate is ranked better than
65.03% of 1307 companies
in the Biotechnology industry
Industry Median: 3.4 vs INO: 14.40

Inovio Pharmaceuticals's EBIT for the three months ended in Dec. 2023 was $-24.72 Mil.

Inovio Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Inovio Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals EBIT per Share Chart

Inovio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-13.72

-11.93

-17.31

-13.90

-6.04

Inovio Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-2.59	-1.87	-1.60	-1.50	-1.09

Inovio Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Inovio Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-133.895	/	22.174
=	-6.04

Inovio Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.721	/	22.734
=	-1.09

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.06

Inovio Pharmaceuticals (NAS:INO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Inovio Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

INO:Mexico GBMB:Germany GBMB:Germany

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Executives

Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
David B. Weiner	director	717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner	officer: Chief Medical Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau	officer: Chief Scientific Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea	officer: Chief Operating Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies	officer: CFO
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim	director, officer: Chief Executive Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard	director	15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno	director
Morton Collins	director
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai	officer: Chief Operating Officer	VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422